Adagene Inc.
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Adagene Inc. is a clinical-stage biopharmaceutical company focused on advancing antibody-based cancer immunotherapies through innovative proprietary platforms. It specializes in the discovery, development, and production of monoclonal antibodies targeting key immune checkpoints and pathways to treat advanced solid tumors, non-Hodgkin's lymphoma, and other cancers. Notable programs include ADG126, a lead SAFEbody targeting CTLA-4 designed to improve safety; ADG116, a novel CTLA-4 antagonist using NEObody technology for effective Treg depletion; ADG106, a CD137 agonist with a unique mechanism; ADG104, an anti-PD-L1 antibody; ADG125, an anti-CSF-1R antibody; and ADG206 for solid tumors, alongside preclinical assets like POWERbody bispecifics and additional SAFEbodies. Adagene Inc. leverages platforms such as SAFEbody for protease-activated masking to enhance therapeutic windows and NEObody for precise epitope targeting, enabling differentiated immunotherapy modalities. Founded in 2011 and headquartered in Suzhou, China, the company plays a significant role in global oncology innovation by addressing limitations in existing treatments.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Peter P. Luo Ph.D.
- Employees
- 128
- Headquarters
- Suzhou, China
- Website
- www.adagene.com